Literature DB >> 18364716

Does the yield of prostate cancer biopsy and repeat biopsy justify the frequency of their use?

Joseph Presti1.   

Abstract

Entities:  

Year:  2008        PMID： 18364716     DOI： 10.1038/ncpuro1056

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN： 1743-4270


× No keyword cloud information.
  7 in total

Review 1.  Advancements in MR imaging of the prostate: from diagnosis to interventions.

Authors:  David Bonekamp; Michael A Jacobs; Riham El-Khouli; Dan Stoianovici; Katarzyna J Macura
Journal:  Radiographics       Date:  2011 May-Jun       Impact factor: 5.333

2.  Comparative efficiency of contrast-enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection.

Authors:  Michael Josef Mitterberger; Friedrich Aigner; Wolfgang Horninger; Hanno Ulmer; Silvio Cavuto; Ethan J Halpern; Ferdinand Frauscher
Journal:  Eur Radiol       Date:  2010-06-23       Impact factor: 5.315

Review 3.  Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors:  Hossein Jadvar
Journal:  Abdom Radiol (NY)       Date:  2016-05

Review 4.  Advancements in magnetic resonance-guided robotic interventions in the prostate.

Authors:  Katarzyna J Macura; Dan Stoianovici
Journal:  Top Magn Reson Imaging       Date:  2008-12

5.  Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy.

Authors:  Misop Han; Doyoung Chang; Chunwoo Kim; Brian J Lee; Yihe Zuo; Hyung-Joo Kim; Doru Petrisor; Bruce Trock; Alan W Partin; Ronald Rodriguez; H Ballentine Carter; Mohamad Allaf; Jongwon Kim; Dan Stoianovici
Journal:  J Urol       Date:  2012-10-22       Impact factor: 7.450

6.  Optimization of training and measurement protocol for eNose analysis of urine headspace aimed at prostate cancer diagnosis.

Authors:  Laura Capelli; Carmen Bax; Fabio Grizzi; Gianluigi Taverna
Journal:  Sci Rep       Date:  2021-10-22       Impact factor: 4.379

7.  Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.

Authors:  Bogdan Mitran; Helge Thisgaard; Sara Rinne; Johan Hygum Dam; Frishta Azami; Vladimir Tolmachev; Anna Orlova; Ulrika Rosenström
Journal:  Sci Rep       Date:  2019-11-19       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.